These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36584835)

  • 1. SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    Am J Ophthalmol; 2023 Apr; 248():157-163. PubMed ID: 36584835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
    JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    Ophthalmology; 2023 Oct; 130(10):1066-1072. PubMed ID: 37220815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
    Ip MS; Oden NL; Scott IU; VanVeldhuisen PC; Blodi BA; Ghuman T; Baker CW;
    JAMA Ophthalmol; 2019 Mar; 137(3):281-287. PubMed ID: 30589922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
    JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
    JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCORE2 Report 2: Study Design and Baseline Characteristics.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU;
    Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
    Aref AA; Scott IU; VanVeldhuisen PC; King J; Ip MS; Blodi BA; Oden NL;
    JAMA Ophthalmol; 2021 Dec; 139(12):1285-1291. PubMed ID: 34709363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
    JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1491-1500. PubMed ID: 34842984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion.
    Scott IU; VanVeldhuisen PC; Oden NL; Ip MS; Blodi BA;
    Am J Ophthalmol; 2022 Aug; 240():330-341. PubMed ID: 35461831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.
    Etheridge T; Blodi B; Oden N; Van Veldhuisen P; Scott IU; Ip MS; Mititelu M; Domalpally A
    Ophthalmol Retina; 2021 Oct; 5(10):991-998. PubMed ID: 33373715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.
    Au A; Ip M; Blodi BA; Scott IU; Oden NL; Van Veldhuisen PC; Sarraf D
    Am J Ophthalmol; 2023 Dec; 256():55-62. PubMed ID: 37544495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.
    Gurudas S; Patrao N; Nicholson L; Sen P; Ramu J; Sivaprasad S; Hykin P
    JAMA Ophthalmol; 2022 Feb; 140(2):143-150. PubMed ID: 34989804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
    Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
    JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
    Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
    Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.